July 6, 2026: MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract

MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract

Lyon, France, July 6, 2026 – 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, presents the results of its Annual and Extraordinary General Meeting held on Tuesday, June 16, 2026 at 9:30 am CET at the Company’s office and broadcasted live (replay available here). The Company also provides an update on the liquidity contract managed by Kepler Cheuvreux as of June 30^th, 2026.

Annual and Extraordinary General Meeting

The quorum reached by the shareholders present, representing, or voting remotely, was above 69.61% of voting shares.

Shareholders overwhelmingly approved most of the resolutions put forward by the Board of Directors by a majority of over 90%. The following resolutions were approved:

• Approval of the financial statements for fiscal year 2025;
• The renewal of the terms of office for current directors Mr. Jean-Marie Lefèvre, Mrs. Nadia Kamal, Mr. Claude Bertrand, Mr. Hervé Affagard, Mr. Jean Volatier, Seventure Partners and Bpifrance Investissement;
• The compensation policy for corporate officers (Chairman, Chief Executive Officer and Directors) and the compensation paid or awarded during 2025 fiscal year – details of the votes on the said resolution is available on the Company’s website here;
• Financial resolutions, notably delegations of authority to the Board of Directors to carry out capital increases in various situations.

Only one resolution was rejected:

• Delegation of authority to the Board of Directors to decide on any merger, demerger or partial contribution of assets (29th resolution).

In accordance with the approval of resolutions 19 and 20, the Company also announced that the Board of Directors has decided to maintain the liquidity contract signed with Kepler Cheuvreux for the liquidity of the Company’s shares listed on Euronext Paris. Information on this contract is available in the Company’s Universal Registration Document (French only).

The full minutes of the Annual General Meeting and the results of the votes, resolution by resolution are available on the Company’s website www.maatpharma.com in the Investors/ Shareholder Meetings’ section.

Half-year liquidity contract statement

Under the liquidity contract entered into between MaaT Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30^th, 2026:

–    45,618 shares
–    € 66,564.56

–   Number of executions on buy side on semester: 2,998

–   Number of executions on sell side on semester: 2,808

–   Traded volume on buy side on semester: 222,290 shares for € 1,297,309.11

–   Traded volume on sell side on semester: 203,219 shares for € 1,268,496.55

As a reminder :

• the following resources appeared on the last half-year statement on 31 December 2025 on the liquidity account:
  • 26,547 shares
  • € 94,695.27
  • Number of executions on buy side on semester: 2,120
  • Number of executions on sell side on semester: 2,342
  • Traded volume on buy side on semester: 74,642 shares for € 332,072.16
  • Traded volume on sell side on semester: 83,855 shares for € 394,938.88

• the following resources appeared on the liquidity account when the activity started:
  • 0 shares
  • € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22^nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.